NDA 018240 · Twi Pharms
Tenormin
Atenolol · Oral · beta-Adrenergic Blocker
NovelLast checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Aug 19, 1981
Approved uses
4
Original approval plus efficacy supplements
Registered trials
122
29 Phase 3, 7 recruiting
FAERS reports
133,241
93,431 serious, 11,331 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2025.
INDICATIONS AND USAGE Hypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 1990 Supplement 13 · Efficacy
- Sep 13, 1989 Supplement 5 · Efficacy
- Sep 4, 1985 Supplement 2 · Efficacy
- Aug 19, 1981 Original approval · Type 1 - New Molecular Entity
3 products under this application
- TENORMIN · ATENOLOL 25MG · TABLET, ORAL · Prescription · TE AB
- TENORMIN · ATENOLOL 100MG · TABLET, ORAL · Prescription · TE AB
- TENORMIN · ATENOLOL 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Atenolol" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- The International Polycap Study 3 (TIPS-3)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01646437 · 7,793 participants · Start Jun 2012 · Primary completion Jun 30, 2020
Drug: Polycap; Aspirin and 2 more · For: Cardiovascular Disease; Fractures; Cancers
Sites: Dhaka, Bangladesh; Hamilton, Canada; Bucaramanga, Colombia · 9 sites in all
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)Pivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT03278509 · 5,000 participants (planned) · Start Sep 11, 2017 · Primary completion Nov 16, 2023
Drug: Metoprolol Succinate; Bisoprolol · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Danderyd, Sweden
- Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00263393 · 3,712 participants · Start Dec 2005 · Primary completion Dec 2008
Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin · For: Myocardial Infarction; Angina Pectoris; Cerebrovascular Accidents and 1 more
Sites: Bhimavaram, India
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective8,061
- nausea7,924
- fatigue7,694
- diarrhoea7,124
- dyspnoea6,387
- dizziness6,333
- headache5,989
- pain5,767
- asthenia5,012
- fall4,728
- arthralgia4,669
- malaise4,305
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4,208 |
| 2005 | 4,818 |
| 2006 | 4,685 |
| 2007 | 4,035 |
| 2008 | 4,456 |
| 2009 | 5,158 |
| 2010 | 6,629 |
| 2011 | 6,664 |
| 2012 | 7,429 |
| 2013 | 6,456 |
| 2014 | 8,239 |
| 2015 | 9,678 |
| 2016 | 9,111 |
| 2017 | 8,094 |
| 2018 | 8,469 |
| 2019 | 7,496 |
| 2020 | 6,223 |
| 2021 | 4,826 |
| 2022 | 4,230 |
| 2023 | 3,598 |
| 2024 | 3,327 |
| 2025 | 3,211 |
| 2026 | 2,195 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tenormin (Atenolol)
2024 spending
$3.1M
Beneficiaries
606
2,584 claims
Per beneficiary
$5,079
$12.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,942,434 |
| 2021 | $4,388,570 |
| 2022 | $4,125,527 |
| 2023 | $3,536,522 |
| 2024 | $3,077,659 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bioavailability of atenolol formulations.
Mcainsh J, Simpson WT, Holmes BF, et al. · Biopharm Drug Dispos 1980 · Clinical Trial, Randomized Controlled Trial
- Asthma and beta-blockers.
Lawrence DS, Sahay JN, Chatterjee SS, et al. · Eur J Clin Pharmacol 1982 · Clinical Trial, Randomized Controlled Trial
- Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine.
Stensrud P, Sjaastad O · Ups J Med Sci Suppl 1980 · Clinical Trial, Comparative Study
- Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Chang SW, Gong Y, McDonough CW, et al. · Clin Transl Sci 2016 · Multicenter Study, Randomized Controlled Trial
- Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics.
Montan S, Ingemarsson I, Marsál K, et al. · BMJ 1992 · Clinical Trial, Comparative Study
- Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine.
Stensrud P, Sjaastad O · Headache 1980 · Clinical Trial, Comparative Study
Sponsor: Twi Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.